Based on the Vivos Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for Vivos Therapeutics Inc is USD 6.03 over the next 12 months. Vivos Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Vivos Therapeutics Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Vivos Therapeutics Inc’s stock price was USD 2.10. Vivos Therapeutics Inc’s stock price has changed by -8.30% over the past week, -41.34% over the past month and -21.05% over the last year.
No recent analyst target price found for Vivos Therapeutics Inc
No recent average analyst rating found for Vivos Therapeutics Inc
Company Overview Vivos Therapeutics Inc
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. Read Less
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical...Read More
Frequently Asked Questions About Vivos Therapeutics Inc (VVOS) Stock
Based on ratings from 2 analysts Vivos Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on VVOS's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for VVOS is USD 6.03 over the next 12 months. The maximum analyst target price is USD 6.6 while the minimum anlayst target price is USD 5.5.
Unfortunately we do not have enough data on VVOS's stock to indicate if its overvalued.
The last closing price of VVOS's stock was USD 2.10.
The most recent market capitalization for VVOS is USD 0.01B.
Based on targets from 2 analysts, the average taret price for VVOS is projected at USD 6.03 over the next 12 months.
This means that VVOS's stock price may go up by +187.30% over the next 12 months.
We can't find any ETFs which contains Vivos Therapeutics Inc's stock.
As per our most recent records Vivos Therapeutics Inc has 114 Employees.
Vivos Therapeutics Inc's registered address is 7921 Southpark Plaza, Littleton, CO, United States, 80120.
You can get more information about it from Vivos Therapeutics Inc's website at https://www.vivos.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Vivos Therapeutics Inc (VVOS) Stock
Based on ratings from 2 analysts Vivos Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and hold ratings.
Unfortunately we do not have enough data on VVOS's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for VVOS is USD 6.03 over the next 12 months. The maximum analyst target price is USD 6.6 while the minimum anlayst target price is USD 5.5.
Unfortunately we do not have enough data on VVOS's stock to indicate if its overvalued.
The last closing price of VVOS's stock was USD 2.10.
The most recent market capitalization for VVOS is USD 0.01B.
Based on targets from 2 analysts, the average taret price for VVOS is projected at USD 6.03 over the next 12 months.
This means that VVOS's stock price may go up by +187.30% over the next 12 months.
We can't find any ETFs which contains Vivos Therapeutics Inc's stock.
As per our most recent records Vivos Therapeutics Inc has 114 Employees.
Vivos Therapeutics Inc's registered address is 7921 Southpark Plaza, Littleton, CO, United States, 80120.
You can get more information about it from Vivos Therapeutics Inc's website at https://www.vivos.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VVOS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
